Robert Hopfner - Mar 27, 2023 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Role
Director
Signature
/s/ Robert Hopfner
Stock symbol
INZY
Transactions as of
Mar 27, 2023
Transactions value $
$841,063
Form type
4
Date filed
3/29/2023, 07:30 PM
Previous filing
Jun 14, 2022
Next filing
Mar 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INZY Common Stock Purchase $189K +51.1K +1.92% $3.70 2.71M Mar 27, 2023 See footnotes F1, F2, F3
transaction INZY Common Stock Purchase $652K +157K +5.78% $4.16 2.87M Mar 28, 2023 See footnotes F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.625 to $3.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).
F2 2,668,450 of the reported shares are held directly by Pivotal bioVenture Partners Fund I, L.P and 43,778 of the reported shares are held by Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").
F3 Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.
F4 The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.64 to $4.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (4).
F5 2,690,845 of the reported shares are held directly by Pivotal bioVenture Partners Fund I, L.P and 178,149 of the reported shares are held by Pivotal bioVenture Partners Fund II, L.P.